XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $86K invested in XTL Biopharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
25% less funds holding
Funds holding: 4 → 3 (-1)
27% less capital invested
Capital invested by funds: $118K → $86K (-$32K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$27K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Invesco
Atlanta,
Georgia
| $59K | – | – | – |
|
|
2
Morgan Stanley
New York
| $25K | +$3.84K | +400 | +17% |
|
|
3
UBS Group
Zurich,
Switzerland
| $2K | -$5.6K | -584 | -77% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$27K | -2,888 | Closed |
|
XTLB Hedge Fund Activity: Q4 2017 in Review
3 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2017, worth a combined $86K — down 27% from $118K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $3.84K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $27K sold.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2017, down from 4 in Q3 2017.
- Funds reported $86K of XTL Biopharmaceuticals stock for Q4 2017, down 27% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q4 2017 and 1 closed out, a net change of -1 holder.
- The largest XTL Biopharmaceuticals buyer in Q4 2017 was Morgan Stanley, an estimated $3.84K added.
- The largest XTL Biopharmaceuticals seller in Q4 2017 was Susquehanna International Group, an estimated $27K sold.
Based on aggregated 13F filings for Q4 2017.